Floatz logo

Bcma-Cart Cells

Multiple Myeloma

Institute of Hematology & Blood Diseases Hospital, ChinaCell therapyPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
59/ 100

Competitive context

497 Active assets in the Multiple Myeloma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

Bcma-Cart Cells is also rated in:

refractory malignant neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
plasmacytomaDormant
CCC
Indicative ·
48 / 100
View asset →
R2-ISS-IV /MPSS-IVDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →